WEBULL
News
CELG-RT
0.0440
+4.76%
0.0020
Weekly Report: what happened at CELG RT last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at CELG RT last week (1117-1121)?
Weekly Report · 11/24 09:52
Weekly Report: what happened at CELG RT last week (1110-1114)?
Weekly Report · 11/17 09:52
Weekly Report: what happened at CELG RT last week (1103-1107)?
Weekly Report · 11/10 09:50
Weekly Report: what happened at CELG RT last week (1027-1031)?
Weekly Report · 11/03 09:50
Weekly Report: what happened at CELG RT last week (1020-1024)?
Weekly Report · 10/27 09:53
Weekly Report: what happened at CELG RT last week (1013-1017)?
Weekly Report · 10/20 09:50
Weekly Report: what happened at CELG RT last week (1006-1010)?
Weekly Report · 10/13 09:52
Weekly Report: what happened at CELG RT last week (0929-1003)?
Weekly Report · 10/06 09:50
Weekly Report: what happened at CELG RT last week (0922-0926)?
Weekly Report · 09/29 09:50
Weekly Report: what happened at CELG RT last week (0915-0919)?
Weekly Report · 09/22 09:50
Weekly Report: what happened at CELG RT last week (0908-0912)?
Weekly Report · 09/15 09:12
Weekly Report: what happened at CELG RT last week (0901-0905)?
Weekly Report · 09/08 09:13
Weekly Report: what happened at CELG RT last week (0825-0829)?
Weekly Report · 09/01 09:12
Weekly Report: what happened at CELG RT last week (0818-0822)?
Weekly Report · 08/25 09:13
Weekly Report: what happened at CELG RT last week (0811-0815)?
Weekly Report · 08/18 09:13
Weekly Report: what happened at CELG RT last week (0804-0808)?
Weekly Report · 08/11 09:13
Weekly Report: what happened at CELG RT last week (0728-0801)?
Weekly Report · 08/04 09:14
Weekly Report: what happened at CELG RT last week (0721-0725)?
Weekly Report · 07/28 09:14
Weekly Report: what happened at CELG RT last week (0630-0704)?
Weekly Report · 07/07 09:13
More
Webull provides a variety of real-time CELG-RT stock news. You can receive the latest news about Bristol-Myers Squibb Company Celegne Contingent Value Rights through multiple platforms. This information may help you make smarter investment decisions.
About CELG-RT
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.